Volume 23, Number 10—October 2017
Dispatch
Hantavirus Pulmonary Syndrome Caused by Maripa Virus in French Guiana, 2008–2016
Séverine Matheus
, Hatem Kallel, Claire Mayence, Laetitia Bremand, Stéphanie Houcke, Dominique Rousset, Vincent Lacoste, Benoit de Thoisy, Didier Hommel, and Anne Lavergne
, Hatem Kallel, Claire Mayence, Laetitia Bremand, Stéphanie Houcke, Dominique Rousset, Vincent Lacoste, Benoit de Thoisy, Didier Hommel, and Anne Lavergne
Table
Clinical characteristics of 5 male patients infected with Maripa virus, French Guiana, 2008–2016*
| Characteristic | Reference range | Patient |
Mean (min–max) | SD | No. (%) patients | ||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | |||||
| Year case reported | 2008 | 2009 | 2010 | 2013 | 2016 | ||||
| Age, y | 38 | 56 | 49 | 67 | 71 | 56.2 (38.0–71.0) | 13.4 | ||
| Location of residence | Tonate-Macouria | Rémire-Montjoly | Tonate-Macouria | Tonate-Macouria | Iracoubo | ||||
| Day of hospital admission after symptom onset |
7 |
4 |
2 |
4 |
4 |
4.2 (2.0–7.0) |
1.8 |
||
| Characteristics at admission to ICU | |||||||||
| Heart rate, beats/min | 140 | 150 | 140 | 168 | 170 | 154 (140–170) | 15 | ||
| Shock | Yes | Yes | Yes | Yes | Yes | 5 (100) | |||
| Acute lung injury | Yes | Yes | Yes | Yes | Yes | 5 (100) | |||
| Acute kidney injury | Yes | Yes | Yes | Yes | Yes | 5 (100) | |||
| Urea nitrogen, mmol/L | 1.7–8.3 | 9.3 | 10.0 | 10.7 | 13.7 | 6.4 | 10.0 (6.4–13.7) | 2.6 | |
| Creatinine, µmol/L | 62–106 | 192 | 174 | 196 | 196 | 126 | 176.8 (126.0–196.0) | 29.8 | |
| Serum protein, g/L | 60–80 | 44.8 | 69.0 | 30.1 | 57.0 | 55.0 | 51.2 (30.1–69.0) | 14.6 | |
| Lactate, mmol/L | 0.63–2.44 | 2.2 | 8.0 | 5.3 | 3.1 | 5.0 | 4.7 (2.2–8.0) | 2.2 | |
| Leukocytes, ×109 cells/L | 4–10 | 22.5 | 21.1 | 19.5 | 9.6 | 9.7 | 16.5 (9.6–22.5) | 6.3 | |
| Platelet count, ×109/L | 150–400 | 50 | 149 | 67 | 125 | 79 | 94.0 (50.0–149.0) | 41.5 | |
| Hematocrit, % | 38–51 | 50.5 | 66.6 | 55.9 | 52.6 | 41.7 | 53.5 (41.7–66.6) | 9.0 | |
| AST, IU/L | <37 | 17 | 49 | 10 | 18 | 17 | 22.2 (10.0–49.0) | 15.3 | |
| ALT, IU/L | <40 | 31 | 47 | 24 | 58 | 29 | 37.8 (24.0–58.0) | 14.2 | |
| Bilirubin, µmol/L | <17 | 3.4 | 8.2 | 6.0 | 6.0 | 4.6 | 5.6 (3.4–8.2) | 1.8 | |
| CPK, U/L | 38–174 | 215 | 119 | 149 | 181 | 262 | 185.2 (119.0–262.0) | 55.9 | |
| Troponin, µg/L | <0.1 | ND | ND | 0.20 | 0.06 | 0.25 | 0.17 (0.06–0.25) | 0.10 | |
| CRP, mg/L |
<10 |
192.0 |
166.0 |
93.3 |
92.4 |
154 |
139.5 (92.4–192.0) |
44.8 |
|
| Death | No | Yes | Yes | Yes | Yes | 4 (80) | |||
| Time of death after admission, h | NA | 2 | 6 | 16 | 14 | 9.5 (2.0–16.0) | 6.6 | ||
*ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; CRP, C-reactive protein; ICU, intensive care unit; max, maximum; min, minimum; NA, not applicable; ND, not determined.
Page created: September 18, 2017
Page updated: September 18, 2017
Page reviewed: September 18, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.